Elon Musk merged SpaceX and xAI ahead of a potential IPO. The move revived hopes—and concerns—about AI convergence across his ...
Nvidia and OpenAI are looking to balance a difficult relationship but reports of a breach should be taken with a grain of ...
One compares her to baseball star Shohei Ohtani, another praises her as a "commoner prime minister". Japan's Sanae Takaichi is generating buzz among Gen-Z in a country where politics has long been ...
Bob Iger’s Second Time as CEO Wasn’t Great for the Stock. He Still Leaves Behind A Strong Legacy.
That’s a large number even for a CEO with outsize compensation, but few shareholders would quibble with the option award.
The penalty is the latest reminder that off-channel communications is still a live issue with regulators.
The Ozempic and Wegovy maker reports full-year sales of 309.1 billion Danish krone, beating analysts’ forecasts.
These financial advisors, all part of Dynasty Financial Partners, emphasize diversification, but tilt towards areas including artificial intelligence, real estate, and defense.
Richmond Fed President Thomas Barkin said the Fed still has “some distance to travel” before both parts of its dual mandate ...
Palantir Technologies, the most expensive stock in the S&P 500 index, might also be one of a handful of companies capable of performing one of the most crucial tasks in the current economy.
(NYSE: CTVA) ("Corteva" or the "Company") today reported financial results for the fourth quarter and full-year ended December 31, 2025.
Shares of Sagimet Biosciences were up as much as 12% after encouraging clinical trial results for its acne treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results